Page 1

RD Gente , Saúde e Bem - estar . RaiaDrogasil S.A. EARNINGS RELEASE 3Q21 Raia Rala DROGASIL + DROGASIL São Paulo , November 09 , 2021. RD - People , Health and Well - being ( Raia Drogasil S.A. – B3 : RADL3 ) announces today its results for the 3rd quarter of 2021 ( 3Q21 ) . The Company's parent company and consolidated interim financial statements for the periods ended September 30 , 2021 and 2020 have been prepared in accordance with the accounting practices adopted in Brazil , including the rules issued by the Brazilian Securities Commission ( CVM ) , the Brazilian Accounting Standards - General Technical ( NBC TG ) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee ( CPC ) , and are in conformity with the International Financial Reporting Standards ( IFRS ) issued by the International Accounting Standards Board ( IASB ) , and provide all the significant information related solely to the interim financial statements , which is consistent with the information used by management . The financial statements were prepared in Reais and all growth rates , unless otherwise stated , relate to the same period of 2020 . Since 2019 , our financial statements have been prepared in accordance with IFRS 16. In order to better represent the economics of the business , the figures in this report are presented under IAS 17 / CPC 06 , the previous reporting standard . Reconciliation with IFRS 16 can be found on pages 11 and 12 . QUARTERLY HIGHLIGHTS : > PHARMACIES : 2,414 units in operation ( 52 openings and 12 closures ) > MARKET SHARE : 1.1 p.p. increase to 14.3 % , with gains in every region > GROSS REVENUE : R $ 6.5 billion , a 21.2 % increase with a 2.0 % real mature - store growth > CONTRIBUTION MARGIN * : 10.0 % , a 0.1 p.p. margin expansion and 22 % growth > ADJUSTED EBITDA : R $ 446.2 million , a 6.8 % EBITDA margin and 12 % growth > ADJUSTED NET INCOME : R $ 173.6 million , with a 2.7 % net margin > CASH FLOW : R $ 73.2 million positive free cash flow , R $ 21.9 million total cash consumption * Margin before corporate overhead ( gross profit - selling expenses ) RADL3 R $ 24.20 / share NUMBER OF SHARES 1,651,930,000 MARKET CAP R $ 40.0 billion CLOSING November 8th , 2021 IR CONTACTS : Eugênio De Zagottis Fernando Spinelli André Stolfi Natália Mizutani SITE : ir.rd.com.br Summary ( R $ thousand ) 3Q20 4Q20 1Q21 2Q21 3Q21 # of Pharmacies 2,220 2,299 2,319 2,374 2,414 Organic Openings Closures 64 82 40 662 52 ( 3 ) ( 3 ) ( 20 ) ( 7 ) ( 12 ) 4Bio 3 4 4 4 4 # of Stores - Pharmacies + 4Bio 2,223 2,303 2,323 2,378 2,418 Headcount ( EOP ) 43,223 Pharmacist Count ( EOP ) 8,658 44,631 8,788 45,532 9,088 47,208 48,481 9,346 9,676 # of Tickets ( 000 ) 60,298 67,098 65,660 66,911 71,115 Gross Revenue 5,384,230 5,868,052 5,979,508 6,245,163 6,527,875 Gross Profit % of Gross Revenues 1,494,996 27.8 % 1,634,213 27.8 % 1,641,852 27.5 % 1,797,052 28.8 % 1,815,460 27.8 % Adjusted EBITDA 397,159 % of Gross Revenues 7.4 % 430,843 7.3 % 415,855 7.0 % 497,115 8.0 % 446,165 6.8 % Adjusted Net Income % of Gross Revenues 172,871 3.2 % 213,672 3.6 % 177,947 3.0 % 232,022 3.7 % 173,567 2.7 % Net Income 174,717 % of Gross Revenues 3.2 % 198,492 3.4 % 188,789 3.2 % 266,443 4.3 % 172,765 2.6 % E - MAIL : ri@rd.com.br Free Cash Flow 351,792 418,767 ( 119,282 ) ( 302,106 ) 73,159 IBRX50 B3 IBRAB3 IGCT B3 ITAG B3 IGC - NM B3 ICON B3 MLCXB3 ICO2 B3 RADL 83 LISTED NM